Synergy of TRIF-dependent TLR3 and MyD88-dependent TLR7 in up-regulating expression of mouse FPR2, a promiscuous G-protein-coupled receptor, in microglial cells

Journal of Neuroimmunology

Volumn 213, Issue 1-2, 2009, Pages 69-77

  Chen, Keqiang ^a,b   Huang, Jian ^b,c   Liu, Ying ^b   Gong, Wanghua ^d   Cui, Youhong ^c   Wang, Ji Ming ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Center for Cancer Research   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d SAIC FREDERICK INC   (United States)

Author keywords

Cooperation; mFPR2; Microglia; TLR3; TLR7

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; I KAPPA B ALPHA; IMIQUIMOD; LUMICAN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENCEPHALITIS; IMMUNOPATHOGENESIS; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; RNA VIRUS; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; AMINOQUINOLINES; ANIMALS; CELL LINE; DRUG SYNERGISM; ENCEPHALITIS; GLIOSIS; I-KAPPA B PROTEINS; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; MICE; MICROGLIA; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHORYLATION; POLY I-C; RECEPTORS, FORMYL PEPTIDE; RNA VIRUS INFECTIONS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 7; UP-REGULATION;

EID: 68049135718     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.05.018     Document Type: Article

References (41)

1. Alexopoulou L., Holt A.C., Medzhitov R., and Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 (2001) 732-738
2. Bagchi A., Herrup E.A., Warren H.S., Trigilio J., Shin H.S., Valentine C., and Hellman J. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 178 (2007) 1164-1171
3. Bsibsi M., Ravid R., Gveric D., and van Noort J.M. Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 61 (2002) 1013-1021
4. Chen K., Iribarren P., Hu J., Chen J., Gong W., Cho E.H., Lockett S., Dunlop N.M., and Wang J.M. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid beta peptide. J. Biol. Chem. 281 (2006) 3651-3659
5. Chen K., Iribarren P., Huang J., Zhang L., Gong W., Cho E.H., Lockett S., Dunlop N.M., and Wang J.M. Induction of the formyl peptide receptor 2 in microglia by IFN-gamma and synergy with CD40 ligand. J. Immunol. 178 (2007) 1759-1766
6. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., and Wang J.M. Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 7 (2007) 1271-1285
7. Chen K., Zhang L., Huang J., Gong W., Dunlop N.M., and Wang J.M. Cooperation between NOD2 and Toll-like receptor 2 ligands in the up-regulation of mouse mFPR2, a G-protein-coupled Abeta42 peptide receptor, in microglial cells. J. Leukoc. Biol. 83 (2008) 1467-1475
8. Cui Y.H., Le Y., Gong W., Proost P., Van Damme J., Murphy W.J., and Wang J.M. Bacterial lipopolysaccharide selectively up-regulates the function of the chemotactic peptide receptor formyl peptide receptor 2 in murine microglial cells. J. Immunol. 168 (2002) 434-442
9. Cui Y., Le Y., Yazawa H., Gong W., and Wang J.M. Potential role of the formyl peptide receptor-like 1 (FPRL1) in inflammatory aspects of Alzheimer's disease. J. Leukoc. Biol. 72 (2002) 628-635
10. Duffy K.E., Lamb R.J., San Mateo L.R., Jordan J.L., Canziani G., Brigham-Burke M., Korteweg J., Cunningham M., Beck H.S., Carton J., Giles-Komar J., Duchala C., Sarisky R.T., and Mbow M.L. Down modulation of human TLR3 function by a monoclonal antibody. Cell. Immunol. 248 (2007) 103-114
11. Gao J.L., Guillabert A., Hu J., Le Y., Urizar E., Seligman E., Fang K.J., Yuan X., Imbault V., Communi D., Wang J.M., Parmentier M., Murphy P.M., and Migeotte I. F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor. J. Immunol. 178 (2007) 1450-1456
12. Gautier G., Humbert M., Deauvieau F., Scuiller M., Hiscott J., Bates E.E., Trinchieri G., Caux C., and Garrone P. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J. Exp. Med. 201 (2005) 1435-1446
13. Hain R., Bieseler B., Kindl H., Schroder G., and Stocker R. Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant. Mol. Biol. 15 (1990) 325-335
14. Hain R., Reif H.J., Krause E., Langebartels R., Kindl H., Vornam B., Wiese W., Schmelzer E., Schreier P.H., Stocker R.H., et al. Disease resistance results from foreign phytoalexin expression in a novel plant. Nature 361 (1993) 153-156
15. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., Lipford G., Wagner H., and Bauer S. Species-specific recognition of single-stranded RNA via Toll-like receptor 7 and 8. Science 303 (2004) 1526-1529
16. Hu J.Y., Le Y., Gong W., Dunlop N.M., Gao J.L., Murphy P.M., and Wang J.M. Synthetic peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1. J. Leukoc. Biol. 70 (2001) 155-161
17. Iribarren P., Chen K., Hu J., Gong W., Cho E.H., Lockett S., Uranchimeg B., and Wang J.M. CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein-coupled receptor mFPR2. Faseb. J. 19 (2005) 2032-2034
18. Iribarren P., Zhou Y., Hu J., Le Y., and Wang J.M. Role of formyl peptide receptor-like 1 (FPRL1/FPR2) in mononuclear phagocyte responses in Alzheimer disease. Immunol. Res. 31 (2005) 165-176
19. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18 (1999) 6867-6874
20. Kovacs G.G., and Budka H. Prion diseases: from protein to cell pathology. Am. J. Pathol. 172 (2008) 555-565
21. Le W., Rowe D., Xie W., Ortiz I., He Y., and Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21 (2001) 8447-8455
22. Le Y., Murphy P.M., and Wang J.M. Formyl-peptide receptors revisited. Trends. Immunol. 23 (2002) 541-548
23. Leonard J.N., Ghirlando R., Askins J., Bell J.K., Margulies D.H., Davies D.R., and Segal D.M. The TLR3 signaling complex forms by cooperative receptor dimerization. PNAS 105 (2008) 258-263
24. Liu L., Botos I., Wang Y., Leonard J.N., Shiloach J., Segal D.M., and Davies D.R. Structural basis of Toll-like receptor 3 signaling with double-stranded RNA. Science 18, 320 5874 (2008) 379-381
25. Lockhart B.P., Cressey K.C., and Lepagnol J.M. Suppression of nitric oxide formation by tyrosine kinase inhibitors in murine N9 microglia. Br. J. Pharmacol. 123 (1998) 879-889
26. Matsumoto M., Kikkawa S., Kohase M., Miyake K., and Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem. Biophys. Res. Commun. 24;293 5 (2002) 1364-1369
27. McKimmie C.S., and Fazakerley J.K. In response to pathogens, glial cells dynamically and differentially regulate Toll-like receptor gene expression. J. Neuroimmunol. 169 (2005) 116-125
28. Monsonego A., and Weiner H.L. Immunotherapeutic approaches to Alzheimer's disease. Science 302 (2003) 834-838
29. Napolitani G., Rinaldi A., Bertoni F., Sallusto F., and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6 (2005) 769-776
30. Nelson P.T., Soma L.A., and Lavi E. Microglia in diseases of the central nervous system. Ann. Med. 34 (2002) 491-500
31. Ouyang X., Negishi H., Takeda R., Fujita Y., Taniguchi T., and Honda K. Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. Biochem. Biophys. Res. Commun. 354 (2007) 1045-1051
32. Righi M., Mori L., De Libero G., Sironi M., Biondi A., Mantovani A., Donini S.D., and Ricciardi-Castagnoli P. Monokine production by microglial cell clones. Eur. J. Immunol. 19 (1989) 1443-1448
33. Rock R.B., Gekker G., Hu S., Sheng W.S., Cheeran M., Lokensgard J.R., and Peterson P.K. Role of microglia in central nervous system infections. Clin. Microbiol. Rev. 17 (2004) 942-964
34. Roelofs M.F., Joosten L.A., Abdollahi-Roodsaz S., van Lieshout A.W., Sprong T., van den Hoogen F.H., van den Berg W.B., and Radstake T.R. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis. Rheum. 52 (2005) 2313-2322
35. Saito T., and Gale Jr. M. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp. Med. 205 (2008) 1523-1527
36. Tahara K., Kim H.D., Jin J.J., Maxwell J.A., Li L., and Fukuchi K. Role of Toll-like receptor signalling in Abeta uptake and clearance. Brain 129 (2006) 3006-3019
37. Theiner G., Rossner S., Dalpke A., Bode K., Berger T., Gessner A., and Lutz M.B. TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol. Immunol. 45 (2008) 244-252
38. Trinchieri G., and Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7 (2007) 179-190
39. Wang T., Town T., Alexopoulou L., Anderson J.F., Fikrig E., and Flavell R.A. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10 (2004) 1366-1373
40. Whitmore M.M., DeVeer M.J., Edling A., Oates R.K., Simons B., Lindner D., and Williams B.R. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer. Res. 64 (2004) 5850-5860
41. Youn H.S., Lee J.Y., Fitzgerald K.A., Young H.A., Akira S., and Hwang D.H. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J. Immunol. 175 (2005) 3339-3346